News

Coya Therapeutics enrolls 100th patient in ALSTARS trial of COYA 302 for ALS, reaching a key recruitment milestone for...

BH-30643 achieves 45% response rate in osimertinib-resistant NSCLC patients with C797S mutations, showing 88% disease control in Phase 1/2...

Summit Therapeutics presents updated overall survival results for ivonescimab in EGFR-mutated NSCLC from the Phase III HARMONi trial.

Roche's Lunsumio combo met its primary endpoint in Phase III follicular lymphoma trial, beating rituximab plus lenalidomide on progression-free...

Mednet AI intake tool automates EHR-to-EDC data entry in clinical trials, reducing manual transcription and entry errors for research...

Hinge Bio runs its Phase I trial on a single Medrio platform, consolidating EDC, ePRO, and RTSM to reduce...

Pulse Biosciences closes enrollment in PRECISE-BTN Thyroid Nodule trial with first patient completing follow-up, positioning for primary dataset readout...

FDA aligns on RP-A501 Phase 2 trial design for Danon disease, approving a 12-patient pivotal population and 12-month endpoint...

CRB-913 obesity drug achieved 5% weight loss in Phase 1b trial, signaling potential for a peripheral CB1 mechanism without...

TRUTAKNA meets all endpoints in Phase 3 IgA Nephropathy Trial final analysis, confirming eGFR stabilization and disease progression prevention...